Bristol Myers Squibb announced that the European Commission has approved CAMZYOS for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. CAMZYOS is the first and only allosteric and reversible inhibitor selective for cardiac myosin approved in all European Union member states and is the first cardiac myosin inhibitor that targets the underlying pathophysiology of HCM. The EC approval of CAMZYOS is based upon positive efficacy and safety results from two Phase 3 trials, EXPLORER-HCM and VALOR-HCM. “This approval marks an important milestone for patients in Europe who will now have a therapeutic option in CAMZYOS, a first-in-class cardiac myosin inhibitor that treats the underlying pathophysiology of symptomatic obstructive HCM,” said Samit Hirawat, M.D., chief medical officer, Bristol Myers Squibb. “We’re proud to bring this innovative treatment to more patients around the world, while reinforcing our ongoing dedication to transforming patients’ lives through science on a global scale.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY:
- Bristol Myers Squibb call volume above normal and directionally bullish
- Cytokinetics price target raised to $54 from $52 at JPMorgan
- Juno Therapeutics’ treatment of multiple myeloma receives FDA orphan designation
- Bristol-Myers sues, calls Inflation Reduction Act provisions ‘unconstitutional’
- Bristol-Myers announces primary analysis results from TRANSCEND trials